文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

Acoramidis治疗ATTR-CM的长期疗效与安全性:ATTRibute-CM开放标签扩展研究初步报告

Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial.
PubMed 文献 · Circulation · 2024-11-18

ATTRibute-CM开放标签扩展研究纳入389例转甲状腺素蛋白淀粉样心肌病患者,比较持续使用acoramidis与安慰剂后换用acoramidis的疗效。至第42个月,持续用药组全因死亡或首次心血管住院风险比为0.57,安全性良好,未发现新的临床重要安全问题。

要点

  • 持续使用acoramidis至第42个月可降低全因死亡或首次心血管住院风险。
  • 安慰剂换用acoramidis后血清转甲状腺素蛋白水平迅速升高。
  • 长期治疗未发现新的临床重要安全性问题。

核心结论

  • 早期启动并持续使用acoramidis至开放标签扩展研究第42个月,与持续临床获益相关,且未新发现临床重要安全问题。

研究设计与样本

  • ATTRibute-CM为3期随机对照研究,完成治疗的438例中389例进入开放标签扩展研究,其中持续acoramidis组263例,安慰剂换用acoramidis组126例。

主要发现

  • 第42个月时,全因死亡或首次心血管住院的风险比为0.57(95%CI 0.46-0.72,P<0.0001),支持持续acoramidis组。
  • 第42个月时,全因死亡单独风险比为0.64(95%CI 0.47-0.88),首次心血管住院单独风险比为0.53(95%CI 0.41-0.69)。
  • NT-proBNP和6分钟步行距离的治疗效应也支持持续acoramidis组。
  • 安慰剂换用acoramidis组启动开放标签治疗后,血清转甲状腺素蛋白迅速升高。
  • 持续acoramidis组较安慰剂换用acoramidis组的堪萨斯城心肌病问卷总体总结评分保持良好。

临床怎么用

  • 对于转甲状腺素蛋白淀粉样心肌病患者,早期启动并持续使用acoramidis可能带来持续临床获益。
  • 长期使用acoramidis至第42个月未发现新的临床重要安全问题,支持其长期应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the phase 3 randomized controlled study ATTRibute-CM (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy), acoramidis, a transthyretin stabilizer, demonstrated significant efficacy on the primary end point. Participants with transthyretin amyloid cardiomyopathy who completed ATTRibute-CM were invited to enroll in an open-label extension study (OLE). We report the efficacy and safety data of acoramidis in participants who completed ATTRibute-CM and enrolled in the ongoing OLE. METHODS: Participants who previously received acoramidis through month 30 in ATTRibute-CM continued to receive it (continuous acoramidis), and those who received placebo through month 30 were switched to acoramidis (placebo to acoramidis). Participants who received concomitant tafamidis in ATTRibute-CM were required to discontinue it to be eligible to enroll in the OLE. Clinical efficacy outcomes analyzed through month 42 included time to event for all-cause mortality (ACM) or first cardiovascular-related hospitalization (CVH), ACM alone, first CVH alone, ACM or recurrent CVH, change from baseline in NT-proBNP (N-terminal pro-B-type natriuretic peptide), 6-minute walk distance, serum transthyretin, and Kansas City Cardiomyopathy Questionnaire Overall Summary score. Safety outcomes were analyzed through month 42. RESULTS: Overall, 438 of 632 participants in ATTRibute-CM completed treatment, and 389 enrolled in the ongoing OLE (263 continuous acoramidis and 126 placebo to acoramidis). The hazard ratio for ACM or first CVH was 0.57 (95% CI, 0.46-0.72) at month 42 based on a stratified Cox proportional hazards model (P<0.0001) favoring continuous acoramidis. Similar analyses were performed on ACM alone and first CVH alone, with hazard ratios of 0.64 (95% CI, 0.47-0.88) and 0.53 (95% CI, 0.41-0.69), respectively, at month 42. Treatment effects for NT-proBNP and 6-minute walk distance also favored continuous acoramidis. On initiation of open-label acoramidis in the placebo-to-acoramidis arm, there was a prompt increase in serum transthyretin. Quality of life assessed by Kansas City Cardiomyopathy Questionnaire Overall Summary score was well preserved in continuous-acoramidis participants compared with the placebo-to-acoramidis participants. No new clinically important safety issues were identified in this long-term evaluation. CONCLUSIONS: Early initiation and continuous use of acoramidis in the ATTRibute-CM study through month 42 of the ongoing OLE study were associated with sustained clinical benefits in a contemporary transthyretin amyloid cardiomyopathy cohort, with no clinically important safety issues newly identified. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04988386.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Judge DP, Gillmore JD, Alexander KM, et al. Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial. Circulation. 2024. PMID: 39556242. doi:10.1161/CIRCULATIONAHA.124.072771

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。